Clinical Trial Update: A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase IIa open-label, dose-escalation trial evaluating tolerability and pharmacokinetics of ZD4054 (zibotentan) given orally once daily in patients with metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Zibotentan (zibotentan)

Snippet

Sponsor: AstraZeneca | Conditions: Prostatic Neoplasms, Metastases, Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2012-08-31